Catalyst Biosciences Inc.

1.51-0.0800-5.03%Vol 578.41K1Y Perf -65.43%
Jun 28th, 2022 16:00 DELAYED
BID1.50 ASK1.59
Open1.55 Previous Close1.59
Pre-Market- After-Market1.51
 - -  - -%
Target Price
9.00 
Analyst Rating
Moderate Buy 1.67
Potential %
496.03 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★+     44.60
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
23.92 
Earnings Rating
Neutral
Market Cap46.48M 
Earnings Date
4th Aug 2022
Alpha0.00 Standard Deviation0.33
Beta1.90 

Today's Price Range

1.451.58

52W Range

0.35015.20

5 Year PE Ratio Range

-1.70-0.9000

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
17.78%
1 Month
29.27%
3 Months
131.81%
6 Months
68.97%
1 Year
-65.43%
3 Years
-78.43%
5 Years
-65.43%
10 Years
-99.52%

TickerPriceChg.Chg.%
CBIO1.51-0.0800-5.03
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
2.70
2.80
0.01
0.07
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-0.50
-1 202.70
-1 197.30
-201 808.00
-
RevenueValueIndustryS&P 500US Markets
6.67M
0.22
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.56-0.4617.86
Q04 2021-0.54-0.64-18.52
Q03 2021-0.66-0.80-21.21
Q02 2021-0.68-0.645.88
Q01 2021-0.77-0.79-2.60
Q04 2020-0.89-0.863.37
Q03 2020-0.95-0.7323.16
Q02 2020-1.05-0.968.57
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.4373.29Positive
9/2022 QR-0.48--
12/2022 FY-1.78--
12/2023 FY-0.56--
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.22
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume578.41K
Shares Outstanding30.78K
Shares Float31.26M
Trades Count1.87K
Dollar Volume871.75K
Avg. Volume2.76M
Avg. Weekly Volume803.17K
Avg. Monthly Volume1.65M
Avg. Quarterly Volume5.83M

Catalyst Biosciences Inc. (NASDAQ: CBIO) stock closed at 1.59 per share at the end of the most recent trading day (a 5.3% change compared to the prior day closing price) with a volume of 681.28K shares and market capitalization of 46.48M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 34 people. Catalyst Biosciences Inc. CEO is Nassim Usman.

The one-year performance of Catalyst Biosciences Inc. stock is -65.43%, while year-to-date (YTD) performance is 73.96%. CBIO stock has a five-year performance of -65.43%. Its 52-week range is between 0.3501 and 5.2, which gives CBIO stock a 52-week price range ratio of 23.92%

Catalyst Biosciences Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 1.75, a price-to-sale (PS) ratio of 7.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -104.81%, a ROC of -118.98% and a ROE of -127.67%. The company’s profit margin is -%, its EBITDA margin is -1 197.30%, and its revenue ttm is $6.67 Million , which makes it $0.22 revenue per share.

Of the last four earnings reports from Catalyst Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Catalyst Biosciences Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Catalyst Biosciences Inc. is Moderate Buy (1.67), with a target price of $9, which is +496.03% compared to the current price. The earnings rating for Catalyst Biosciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.01, ATR14 : 0.16, CCI20 : 145.84, Chaikin Money Flow : 0.25, MACD : 0.18, Money Flow Index : 77.86, ROC : 18.66, RSI : 69.06, STOCH (14,3) : 93.75, STOCH RSI : 0.95, UO : 54.48, Williams %R : -6.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Biosciences Inc. in the last 12-months were: Grant E. Blouse (Buy at a value of $5 705), Howard Levy (Buy at a value of $2 313), Nassim Usman (Buy at a value of $4 634), Seline Miller (Buy at a value of $1 495)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (25.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Strong Buy
1.50
Strong Buy
1.50

Catalyst Biosciences Inc.

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes on product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

CEO: Nassim Usman

Telephone: +1 650 871-0761

Address: 611 Gateway Boulevard, South San Francisco 94080, CA, US

Number of employees: 34

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

63%37%

Bearish Bullish

62%38%

TipRanks News for CBIO

Thu, 17 Mar 2022 11:59 GMT Catalyst Biosciences (CBIO) Receives a Buy from LifeSci Capital

- TipRanks. All rights reserved.

News

Stocktwits